Companies → Cardinal Health, Inc.
Save to list
Remove

Cardinal Health, Inc.

United States, Ohio, Dublin
Description
Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. Its pharmaceutical segment provides supply chain services including branded, generic, and specialty pharmaceutical and OTC drug distribution. Cardinal's medical division parcels out medical, laboratory, and surgical supplies. It sells manufactured products in the US, Canada, Europe, Asia, Latin America and other markets. Customers include retail pharmacies (including chain and independent drug stores and pharmacy departments of supermarkets and mass merchandisers), hospitals, health care systems, surgery centers, nursing homes, doctor's offices, clinical labs, and other health care businesses. The US accounts for the majority of Cardinal's revenue.
Address:

7000 Cardinal Pl Dublin

OH

43017-1091 United States

Revenue
Recent news:

Cardinal Health (CAH) Stock Moves -1.47%: What You Should Know

Cardinal Health (CAH) concluded the recent trading session at $207.83, signifying a -1.47% move from its prior day's close.

Source: Zacks Mar 20, 2026

Here's Why You Should Retain AMN HealthCare Stock in Your Portfolio

AMN rides MSP momentum, AI investments and surging labor disruption demand, but pricing pressure and volatile healthcare trends cloud its near-term outlook.

Source: Zacks Mar 20, 2026

What Powers BWXT's Strength in Nuclear Medicine Manufacturing?

BWX Technologies expands beyond defense, boosting nuclear medicine with isotopes, new capabilities and a growing role in cancer diagnostics and treatment.

Source: Zacks Mar 20, 2026

GEHC Acquires Intelerad to Boost Cloud-First, AI Imaging Capabilities

GE HealthCare completes the $2.3B Intelerad deal to expand AI-driven imaging, boost recurring revenues and strengthen its cloud-first healthcare platform.

Source: Zacks Mar 20, 2026

Glaukos Launches Epioxa, Boosts Growth in Corneal Treatments

GKOS launches Epioxa, the first FDA-approved topical keratoconus therapy, targeting an underserved market and positioning the company for long-term growth.

Source: Zacks Mar 20, 2026

Here's Why You Should Add McKesson Stock to Your Portfolio Now

McKesson's strong oncology, GLP-1, and biopharma growth fuel earnings momentum, but margin pressure and segment volatility remain key watch points.

Source: Zacks Mar 20, 2026

NYSE - Delayed Quote - USD
CAH
207.83 -3.09 (-1.47%)
At close March 20 20:00 UTC
209.00 +1.17 (+0.56%)
After hours: March 20 22:00 UTC
Candle
Line
1D
5D
1M
6M
1Y
5Y
Financial Statistics
Valuation Measures
Current
Quarterly
As of 03/20/2026
Market Cap: 48.91 B
Enterprise Value: 55.16 B
Trailing P/E: 29.90
Forward P/E: 18.18
PEG Ratio (5yr expected): 1.34
Price/Sales (ttm): 0.20
Price/Book (mrq): -17.01
Enterprise Value/Revenue: 0.23
Enterprise Value/EBITDA: 15.87
Financial Highlights
Profitability and Income Statement
Profit Margin: 0.68%
Return on Assets (ttm): 3.50%
Return on Equity (ttm): N/A%
Revenue (ttm): 244.67 B
Net Income Avi to Common (ttm): 1.66 B
Diluted EPS (ttm): 6.94
Balance Sheet and Cash Flow
Total Cash (mrq): 2.78 B
Total Debt/Equity (mrq): N/A%
Levered Free Cash Flow (ttm): 5.44 B
Company is likely to buy
Disclaimer:

IndexBox is not affiliated with, associated with, or endorsed by this company in any way. The information provided on this page, including company details, is solely for informational purposes. IndexBox makes no representations or warranties about the accuracy or completeness of the information provided.

All data and information is provided “as is” for informational purposes only, and is not intended for trading purposes or financial, investment, tax, legal, accounting or other advice. Please consult your broker or financial representative to verify pricing before executing any trade. IndexBox is not an investment adviser, financial adviser or a securities broker. None of the data and information constitutes investment advice nor an offering, recommendation or solicitation by IndexBox to buy, sell or hold any security or financial product, and IndexBox makes no representation (and has no opinion) regarding the advisability or suitability of any investment.